Replies to post #509900 on NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

I believe you underestimate the hurdles with ROW RAs, government bureaucracy, red tapes, price sensitivity, cloud of internal major pharma groups, local manufacturing requirements, scalability, etc. I live and breathe this world so I speak from direct experience.

Dr. Pazdur has literally no say in how countries like China, India, etc run their health economics, RA, processes, etc. These red tapes and hurdles won’t magically disappear because FDA or MHRA approved the vaccine as SOC for nGBM & rGBM. Hence, it simply doesn’t make sense for NWBO to fight that battle for a very small fraction of population in each region that can afford such treatment. These few wealthy folks will flock to US or UK anyway! It’s unfortunate but that’s the reality on the ground.

Anyway, you are welcome to stick with your theory.

[dr_lowenstein]

Pazdur said nothing about this crap. He was speaking only theoretically about the possiblity of the FDA accepting historical controls - theoretically

[IkeEsq]

I will keep my list of facts the same as they are.

You do realize that four of your 'facts' have not occurred yet and therefore are predictions, not facts, right? Also, in fact 1, I think you mean 'statistical significance,' not 'clinical significance.' Although both may be true, I have only heard statistical significance being reported during the May 10 presentation and otherwise.